Determination of serum biomarkers in osteoarthritis patients: a previous interventional imaging study revisited
Timothy McAlindon, Eckart Bartnik, Janina S Ried, Lenore Teichert, Matthias Herrmann, Klaus Flechsenhar, Timothy McAlindon, Eckart Bartnik, Janina S Ried, Lenore Teichert, Matthias Herrmann, Klaus Flechsenhar
Abstract
To evaluate in an interventional trial on knee osteoarthritis (OA) the level and change of two serum biomarkers and their correlation with imaging parameters. The previously reported interventional OA study (ClinicalTrials.gov: NCT00536302) identified a positive effect of collagen hydrolysate (CH) on cartilage morphology in patients with knee OA using delayed gadolinium enhanced magnetic resonance imaging (dGEMRIC). It was the objective in this research project to evaluate in an interventional clinical trial on knee OA the level and change of two serum biomarkers and their correlation with imaging parameters. In blood samples of study participants, we determined the concentration of procollagen type II N-terminal propeptide (PIIANP) and aggrecan chondroitin sulfate 846 epitope (CS846) at baseline (BL) and at the follow-up (FU) visits at 24 and 48 weeks. We measured the level and change of biomarker concentrations in both study groups, and the correlation of those changes with changes in dGEMRIC. For the biomarker PIIANP, we observed a significantly greater increase in the CH group (29.9% vs. 1.2% at week 24, P= 0.001). For CS846, the mean concentration was lower among the CH treated participants at 24 weeks (78% vs. 96%, P= 0.045). Consistent correlations of changes in biomarkers PIIANP and CS846 with changes of the dGEMRIC score could not be observed. In this study, different changes per treatment group, CH and placebo were seen for dGEMRIC and PIIANP BL to 24 weeks FU, but only weak correlations between changes in dGEMRIC and biochemical markers.
Figures
References
- McAlindon TE, Nuite M, Krishnan N, et al. Change in knee osteoarthritis cartilage detected by delayed gadolinium enhanced magnetic resonance imaging following treatment with collagen hydrolysate: a pilot randomized controlled trial[J]. Osteoarthritis Cartilage, 2011, 19(4): 399–405.
- Benito-Ruiz P, Camacho-Zambrano MM, Carrillo-Arcentales JN, et al. A randomized controlled trial on the efficacy and safety of a food ingredient, collagen hydrolysate, for improving joint comfort[J]. Int J Food Sci Nutr, 2009, 60(Suppl 2): 99–113.
- J Prawitt. Collagen peptides improve knee osteoarthritis in elderly women, a 6 month, randomized, double-blind, placebo-controlled study[J]. Agro Food Ind Hi-Tech, 2014, 25(2): 19–23.
- Oesser S, Adam M, Babel W, et al. Oral administration of (14)C labeled gelatin hydrolysate leads to an accumulation of radioactivity in cartilage of mice (C57/BL)[J]. J Nutr, 1999, 129(10): 1891–1895.
- Oesser S, Seifert J. Stimulation of type II collagen biosynthesis and secretion in bovine chondrocytes cultured with degraded collagen[J]. Cell Tissue Res, 2003, 311(3): 393–399.
- Kraus VB, Burnett B, Coindreau J, et al., and the OARSI FDA Osteoarthritis Biomarkers Working Group. Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis[J]. Osteoarthritis Cartilage, 2011, 19(5): 515–542.
- Nemirovskiy OV, Sunyer T, Aggarwal P, et al. Discovery and development of the N-terminal procollagen type II (NPII) biomarker: a tool for measuring collagen type II synthesis[J]. Osteoarthritis Cartilage, 2008, 16(12): 1494–1500.
- Lohmander LS, Ionescu M, Jugessur H, et al. Changes in joint cartilage aggrecan after knee injury and in osteoarthritis[J]. Arthritis Rheum, 1999, 42(3): 534–544.
- Kraus VB, Hargrove DE, Hunter DJ, et al. Establishment of reference intervals for osteoarthritis related biomarkers - The FNIH/OARSI OA Biomarkers Consortium[J]. Ann Rheum Dis. 2016, pii: . doi: 10.1136/annrheumdis-2016-209253.
Source: PubMed